ClinicalTrials.gg
CompletedNCT07117487Updated May 4, 2026

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

A Phase 3 interventional study of mRNA-1345 in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 11 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.

Enrollment
6th of 10
507 · median 579
Started
2025
the only one that year
Phase 3
4 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
10 of 10
ModernaTX, Inc.

Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 6th largest by enrollment, is the only one that started in 2025, is one of 4 in phase 3, and was the 10th registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →

About mRNA-1345 respiratory syncytial virus vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.

03

Conditions studied

  • Respiratory Syncytial Virus

Browse trials for

Keywords

  • Viral Diseases
  • Messenger RNA
  • Moderna
  • mRNA-1345
  • Respiratory syncytial virus
  • Safety
  • Vaccines
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by:

    • Absence of changes in medical therapy within 60 days of Visit 1 due to treatment failure or toxicity.
    • Absence of serious or significant medical events within 30 days of Visit 1.
    • Absence of known, current, and life-limiting diagnoses which, in the opinion of the Investigator, would make completion of the protocol unlikely.
  • Participant has received a single dose of Arexvy or Abrysvo at least 12 months prior to Visit 1. Participants must provide proof of RSV vaccination status (including brand and date received) prior to enrollment.

Key Exclusion Criteria:

  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤14 days prior to study injection (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 14 days after the study injection. Nonstudy vaccination(s) should not be delayed.
  • Prior participation in research involving receipt of any RSV product (drug/biologic).
  • Has received systemic immunoglobulins, long-acting biological therapies that affect immune responses (for example, infliximab) or blood products within 90 days prior to Visit 1 or plans to receive them during the study.

Other protocol-specified inclusion and/or exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    mRNA-1345

    Participants will receive a single dose of mRNA-1345 injection administered intramuscularly on Day 1.

    Biological: mRNA-1345

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Day 1 up to Day 7 (7 days post-injection)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Day 1 up to Day 28 (28 days post-injection)

  3. Number of Participants with Medically Attended AEs (MAAEs), Serious AEs (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Discontinuation

    Time frame: Day 1 up to Day 181 (End of study)

  4. Geometric Mean Titer (GMT) of Serum RSV-A Neutralizing Antibodies (Abs) at Day 29

    Time frame: Day 29

  5. GMT of Serum RSV-B Neutralizing Abs at Day 29

    Time frame: Day 29

Secondary outcomes

  1. GMT of Serum RSV-A Neutralizing Abs

    Time frame: Day 1 up to Day 181 (End of study)

  2. Geometric Mean Fold Rise (GMFR) of Serum RSV-A Neutralizing Abs

    Time frame: Day 181

  3. GMT of Serum RSV-B Neutralizing Abs

    Time frame: Day 1 up to Day 181 (End of study)

  4. GMFR of Serum RSV-B Neutralizing Abs

    Time frame: Day 181

  5. Percentage of Participants With Seroresponse in RSV-A Neutralizing Abs

    Time frame: Day 181

  6. Percentage of Participants With Seroresponse in RSV-B Neutralizing Abs

    Time frame: Day 181

  7. Percentage of Participants With ≥2-fold Increase From Baseline in RSV-A Neutralizing Ab Titers

    Time frame: Day 181

  8. Percentage of Participants With ≥2-fold Increase From Baseline in RSV-B Neutralizing Ab Titers

    Time frame: Day 181

07

Study locations

11 sites
  • Velocity Clinical Research, Denver
    Denver, Colorado 80110, United States
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Velocity Clinical Research, Savannah
    Savannah, Georgia 31406, United States
  • Velocity Clinical Research, Valparaiso
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research, Covington
    Covington, Louisiana 70433, United States
  • Velocity Clinical Research, Rockville
    Rockville, Maryland 20854, United States
  • Velocity Clinical Research, Lincoln
    Lincoln, Nebraska 68510, United States
  • Velocity Clinical Research, Medford
    Medford, Oregon 97504, United States
  • Velocity Clinical Research, Austin
    Austin, Texas 78759, United States
  • Velocity Clinical Research, Hampton
    Hampton, Virginia 23666, United States
  • Velocity Clinical Research, Spokane
    Spokane, Washington 99218, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Mar 2026, 7 months.

Of 40 industry-sponsored phase 3 interventional studies under Virus Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 24. This study's 7 months is below that.

Counting every sponsor, half of 57 studies reached it within 14 months; a quarter within 8 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 12, 2025
StartActual
Aug 5, 2025
Primary completionActual
Mar 27, 2026
CompletionActual
Mar 27, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07117487
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Aug 5, 2025
Primary completion
Mar 27, 2026
Completion
Mar 27, 2026
Last update
May 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine

Start the discussion